神州控股(00861.HK)料中期主營業務利潤按年增長雙位數 應佔聯營虧損1.9億人幣
神州控股(00861.HK)預計,截至6月30日止六個月主營業務利潤按年增長雙位數 ,主要是由於大數據和解決方案業務部門的強勁表現所推動,預期該業務部門於有關期間收入增長雙位數。
另外,集團持有19.37%股權的慧聰集團(02280.HK)中期業績錄得虧損。集團亦持有慧聰集團一間從事小額貸款業務的附屬30%股權。受慧聰集團及小額貸款公司虧損影響,集團於有關期間產生應佔聯營公司虧損約1.92億元人民幣。
雖然集團主營業務產生的利潤不受影響和於計入應佔虧損後集團的綜合損益表仍保持盈利,但預期應佔聯營公司及合營企業的虧損將對集團於有關期間的綜合損益表產生負面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.